Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2012-04-30

Clinical Trial Update: Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus [Phase 2]

View source ↗

Summary

A Phase 2 trial of R935788 for systemic lupus erythematosus has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • R935788

Snippet

Sponsor: Rigel Pharmaceuticals | Conditions: Systemic Lupus Erythematosus | Phase 2 | Status: WITHDRAWN